Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN versus HUMATIN.
BACITRACIN-NEOMYCIN-POLYMYXIN vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Apply topically to affected area 2-5 times daily.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
Bacitracin: 1.5 hours (prolonged in renal impairment); Neomycin: 2-3 hours (accumulates with renal dysfunction); Polymyxin B: 6-9 hours (increased in renal impairment).
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Bacitracin: primarily renal (>90% unchanged); Neomycin: renal (30-50% unchanged) with non-renal clearance; Polymyxin: renal excretion of parent drug (60-80% unchanged) with some biliary and fecal elimination.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic